Profile
Anthony E.
Bolton is the founder of Vasogen, Inc. (1992), InterMune Life Sciences, Inc. (1992), and Cardiol Therapeutics, Inc. (2017).
At Vasogen, he held the title of Chief Scientific Officer & Research Director from 1992 to 2008.
At InterMune Life Sciences, he was Vice President-Research from 1992 to 1995.
At Cardiol Therapeutics, he was Chief Scientific Officer from 2017 to 2019.
Dr. Bolton's former jobs include Deputy Director-Immunoassay Research Unit at St. Bartholomew's Hospital from 1976 to 1979, Scientific Director-Biomedical Research Unit at Jessop Hospital For Women from 1992 to 1995, and Head & Professor at Sheffield Hallam University from 1985 to 1992.
Dr. Bolton received his undergraduate degree from the University of London in 1967 and his doctorate from The University of Reading in 1970.
Former positions of Anthony E. Bolton
| Companies | Position | End |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Founder | 01/01/2008 |
| Sheffield Hallam University | Corporate Officer/Principal | 01/01/1995 |
| InterMune Life Sciences, Inc. | Founder | 01/01/1995 |
| Jessop Hospital For Women | Corporate Officer/Principal | 01/01/1995 |
| St. Bartholomew's Hospital | Corporate Officer/Principal | 01/01/1979 |
Training of Anthony E. Bolton
| University of London | Undergraduate Degree |
| The University of Reading | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private companies | 4 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
| St. Bartholomew's Hospital | |
| InterMune Life Sciences, Inc. | |
| Jessop Hospital For Women |
- Stock Market
- Insiders
- Anthony E. Bolton